Thoroughly covers the assessment, diagnosis, and treatment of patients with elevated levels of lipids and lipoproteins, including all the latest research-based recommendations, therapeutic breakthroughs, and related clinical advances
Presents the latest data on clinical guidelines, risk assessments, and established and emerging pharmacologic and nonpharmacologic therapies—all from internationally recognized experts in the field
Features condensed, streamlined content that focuses on clinical applications and applying concepts to the practice setting. Chapters have now been completely reorganized into sections on risk assessment; therapy; new and evolving therapeutic targets and platforms; and special populations
Includes new chapters on Polygenic Risk Scores; Inclisiran; Bempedoic Acid; Selective Peroxisome Proliferator–Activated Receptor–α Modulator: Pemafibrate; Evolving Therapeutic Targets: Lp(a), ANGPTL3, and ApoC-III; New Therapeutic Platforms: Gene Therapy and Genome Editing; and more
Contains new or expanded content on inflammation; genetic testing; troponins for risk assessment; statins and role of bile acid sequestrants, niacin, and fibrates; mAbs; CANTOS and CIRT; colchicine; IL-6; and cellular, molecular, and genetic therapy
Provides treatment algorithms throughout, as well as case vignettes that highlight the most common clinical questions in each chapter
Incorporates the latest guidelines from the AHA, ACC, ESC, and EAS, as well as future directions for ongoing research and emerging applications
Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices
SECTION I INTRODUCTION/BASIC MECHANISMS 1. Overview of Lipids and Atherosclerosis
SECTION II RISK ASSESSMENT 2. Overview of Risk Assessment 3. Measurement of Low- Density Lipoprotein Cholesterol, Non–High- Density Lipoprotein Cholesterol, Apolipoprotein B, and Low- Density Lipoprotein Particle Concentration 4. Triglycerides, Triglyceride- Rich Lipoproteins, and High- Density Lipoprotein in Coronary Heart Disease Risk Assessment 5. Lipoprotein(a) in Cardiovascular Risk Assessment 6. Clinical Evaluation for Genetic Testing and Secondary Causes of Dyslipidemia 7. Polygenic Risk Scores 8. High- Sensitivity C- Reactive Protein 9. Emerging Assays for Risk Assessment 10. Imaging Atherosclerosis for Risk Stratifi cation: Cardiac Computed Tomography and Carotid Ultrasound
SECTION III THERAPY 11. Overview of General Approach to Management of Dyslipidemias 12. Treatment Guidelines Overview: American Heart Association/American College of Cardiology/Multisociety Guideline and Updates 13. Treatment Guidelines Overview: European Society of Cardiology/European Atherosclerosis Society Guidelines 14. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease 15. Updated Clinical Guide to Exercise and Lipids 16. Obesity, Lipids, and Cardiovascular Disease 17. Statins 18. Cholesterol Absorption Inhibitors 19. Omega- 3 Fatty Acids 20. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition 21. Inclisiran 22. Bempedoic Acid 23. Pemafi brate: A New Selective Peroxisome Proliferator–Activated Receptor–_Modulator for Hypertriglyceridemia Management 24. Anti- inflammatory Therapy for Cardiovascular Disease 25. Nutraceuticals and Functional Foods for Cholesterol Reduction
SECTION IV NEW AND EVOLVING THERAPEUTIC TARGETS AND PLATFORMS 26. Evolving Therapeutic Targets: Lipoprotein(a) 27. Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias 28. Evolving Therapeutic Targets: Apolipoprotein C- III 29. Evolving Therapeutic Targets: Cholesteryl Ester Transfer Protein Inhibition 30. Gene Therapy and Therapeutic Genome Editing in Liver for Lipid Disorders
SECTION V SPECIAL PATIENT POPULATIONS 31. Special Patient Populations: Diabetes and Metabolic Syndrome 32. Special Patient Populations: Women and Older Adults 33. Special Patient Populations: Children and Adolescents 34. Special Patient Populations: Familial Hypercholesterolemia and Other Severe Hypercholesterolemias 35. Special Patient Populations: Treatment of Familial Chylomicronemia Syndrome and Sustained Chylomicronemia 36. Special Patient Populations: Acute Coronary Syndromes 37. Special Patient Populations: Transplant Recipients 38. Special Populations: Chronic Kidney Disease 39. Special Patient Populations: Lipid Abnormalities in High- Risk Racial/Ethnic Groups 40. Persons With Human Immunodeficiency Virus
Christie M. Ballantyne, MD, FACP, FACC, Chief, Section of Cardiology, Chief, Section of Cardiovascular Research, Professor of Cardiovascular Medicine, Baylor College of Medicine, Houston, Texas, USA
We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors.
You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer. See the different category headings below to find out more or change your settings.
You may also be able to exercise your privacy choices as described in our Privacy Policy
Manage Consent Preferences
Strictly Necessary Cookies
Always active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. If you do not allow these cookies, you will experience less targeted advertising.